|
|
Blood, 15 June 2004, Vol. 103, No. 12, pp. 4619-4621.
Prepublished online as a Blood First Edition Paper on March 4, 2004; DOI 10.1182/blood-2003-11-3909.
Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY Brief report
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation
Roland Meisel,
Andree Zibert,
Maurice Laryea,
Ulrich Göbel,
Walter Däubener, and
Dagmar Dilloo
From the Clinic of Pediatric Oncology, Hematology and Immunology, University Hospital, Düsseldorf, Germany; Clinic of General Pediatrics, University Hospital, Düsseldorf, Germany; and Institute of Medical Microbiology, University Hospital, Düsseldorf, Germany.
Marrow stromal cells (MSCs) inhibit allogeneic T-cell responses, yet the molecular mechanism mediating this immunosuppressive effect of MSCs remains controversial. Recently, expression of indoleamine 2,3-dioxygenase (IDO), which is induced by interferon- (IFN- ) and catalyzes the conversion from tryptophan to kynurenine, has been identified as a T-cell inhibitory effector pathway in professional antigen-presenting cells. Here we show that human MSCs express IDO protein and exhibit functional IDO activity upon stimulation with IFN- . MSCs inhibit allogeneic T-cell responses in mixed lymphocyte reactions (MLRs). Concomitantly, IDO activity resulting in tryptophan depletion and kynurenine production is detected in MSC/MLR coculture supernatants. Addition of tryptophan significantly restores allogeneic T-cell proliferation, thus identifying IDO-mediated tryptophan catabolism as a novel T-cell inhibitory effector mechanism in human MSCs. As IDO-mediated T-cell inhibition depends on MSC activation, modulation of IDO activity might alter the immunosuppressive properties of MSCs in different therapeutic applications. (Blood. 2004;103:4619-4621)

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. E.J. Reinders, W. E. Fibbe, and T. J. Rabelink
Multipotent mesenchymal stromal cell therapy in renal disease and kidney transplantation
Nephrol. Dial. Transplant.,
October 26, 2009;
(2009)
gfp552v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. M. Brusko
Mesenchymal Stem Cells: A Potential Border Patrol for Transplanted Islets?
Diabetes,
August 1, 2009;
58(8):
1728 - 1729.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ding, D. Xu, G. Feng, A. Bushell, R. J. Muschel, and K. J. Wood
Mesenchymal Stem Cells Prevent the Rejection of Fully Allogenic Islet Grafts by the Immunosuppressive Activity of Matrix Metalloproteinase-2 and -9
Diabetes,
August 1, 2009;
58(8):
1797 - 1806.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C Bocelli-Tyndall, L Bracci, S Schaeren, C Feder-Mengus, A Barbero, A Tyndall, and G C Spagnoli
Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the in vitro proliferation of lymphocytes stimulated by interleukins 2, 7 and 15
Ann Rheum Dis,
August 1, 2009;
68(8):
1352 - 1359.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. L. Highfill, R. M. Kelly, M. J. O'Shaughnessy, Q. Zhou, L. Xia, A. Panoskaltsis-Mortari, P. A. Taylor, J. Tolar, and B. R. Blazar
Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming
Blood,
July 16, 2009;
114(3):
693 - 701.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. M. Spaggiari, H. Abdelrazik, F. Becchetti, and L. Moretta
MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2
Blood,
June 25, 2009;
113(26):
6576 - 6583.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Correale, M. C. Ysrraelit, and M. I. Gaitan
Immunomodulatory effects of Vitamin D in multiple sclerosis
Brain,
May 1, 2009;
132(5):
1146 - 1160.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A Tyndall
Cellular therapy of systemic lupus erythematosus
Lupus,
April 1, 2009;
18(5):
387 - 393.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Maby-El Hajjami, P. Ame-Thomas, C. Pangault, O. Tribut, J. DeVos, R. Jean, N. Bescher, C. Monvoisin, J. Dulong, T. Lamy, et al.
Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase
Cancer Res.,
April 1, 2009;
69(7):
3228 - 3237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Curti, S. Trabanelli, V. Salvestrini, M. Baccarani, and R. M. Lemoli
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Blood,
March 12, 2009;
113(11):
2394 - 2401.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-I. Jeong, S. W. Kim, I. D. Jung, J. S. Lee, J. H. Chang, C.-M. Lee, S. H. Chun, M.-S. Yoon, G. T. Kim, S. W. Ryu, et al.
Curcumin Suppresses the Induction of Indoleamine 2,3-Dioxygenase by Blocking the Janus-activated Kinase-Protein Kinase C{delta}-STAT1 Signaling Pathway in Interferon-{gamma}-stimulated Murine Dendritic Cells
J. Biol. Chem.,
February 6, 2009;
284(6):
3700 - 3708.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Haniffa, M. P. Collin, C. D. Buckley, and F. Dazzi
Mesenchymal stem cells: the fibroblasts' new clothes?
Haematologica,
February 1, 2009;
94(2):
258 - 263.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Rafei, J. Hsieh, S. Fortier, M. Li, S. Yuan, E. Birman, K. Forner, M.-N. Boivin, K. Doody, M. Tremblay, et al.
Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction
Blood,
December 15, 2008;
112(13):
4991 - 4998.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Casiraghi, N. Azzollini, P. Cassis, B. Imberti, M. Morigi, D. Cugini, R. A. Cavinato, M. Todeschini, S. Solini, A. Sonzogni, et al.
Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells
J. Immunol.,
September 15, 2008;
181(6):
3933 - 3946.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Karlsson, S. Samarasinghe, L. M. Ball, B. Sundberg, A. C. Lankester, F. Dazzi, M. Uzunel, K. Rao, P. Veys, K. Le Blanc, et al.
Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses
Blood,
August 1, 2008;
112(3):
532 - 541.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Weiss, J. K. Kolls, L. A. Ortiz, A. Panoskaltsis-Mortari, and D. J. Prockop
Stem Cells and Cell Therapies in Lung Biology and Lung Diseases
Proceedings of the ATS,
July 15, 2008;
5(5):
637 - 667.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Abdi, P. Fiorina, C. N. Adra, M. Atkinson, and M. H. Sayegh
Immunomodulation by Mesenchymal Stem Cells: A Potential Therapeutic Strategy for Type 1 Diabetes
Diabetes,
July 1, 2008;
57(7):
1759 - 1767.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Comoli, F. Ginevri, R. Maccario, M. A. Avanzini, M. Marconi, A. Groff, A. Cometa, M. Cioni, L. Porretti, W. Barberi, et al.
Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation
Nephrol. Dial. Transplant.,
April 1, 2008;
23(4):
1196 - 1202.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Larghero, D Farge, A Braccini, S Lecourt, A Scherberich, E Fois, F Verrecchia, T Daikeler, E Gluckman, A Tyndall, et al.
Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis
Ann Rheum Dis,
April 1, 2008;
67(4):
443 - 449.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Atoui, J.-F. Asenjo, M. Duong, G. Chen, R. C.-J. Chiu, and D. Shum-Tim
Marrow Stromal Cells as Universal Donor Cells for Myocardial Regenerative Therapy: Their Unique Immune Tolerance
Ann. Thorac. Surg.,
February 1, 2008;
85(2):
571 - 579.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-P. Li, S. Paczesny, E. Lauret, S. Poirault, P. Bordigoni, F. Mekhloufi, O. Hequet, Y. Bertrand, J.-P. Ou-Yang, J.-F. Stoltz, et al.
Human Mesenchymal Stem Cells License Adult CD34+ Hemopoietic Progenitor Cells to Differentiate into Regulatory Dendritic Cells through Activation of the Notch Pathway
J. Immunol.,
February 1, 2008;
180(3):
1598 - 1608.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. M. Spaggiari, A. Capobianco, H. Abdelrazik, F. Becchetti, M. C. Mingari, and L. Moretta
Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2
Blood,
February 1, 2008;
111(3):
1327 - 1333.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Li, A. Meinhardt, M.-E. Roehrich, D. Golshayan, J. Dudler, M. Pagnotta, M. Trucco, and G. Vassalli
Indoleamine 2,3-dioxygenase gene transfer prolongs cardiac allograft survival
Am J Physiol Heart Circ Physiol,
December 1, 2007;
293(6):
H3415 - H3423.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Nauta and W. E. Fibbe
Immunomodulatory properties of mesenchymal stromal cells
Blood,
November 15, 2007;
110(10):
3499 - 3506.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Chabannes, M. Hill, E. Merieau, J. Rossignol, R. Brion, J. P. Soulillou, I. Anegon, and M. C. Cuturi
A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells
Blood,
November 15, 2007;
110(10):
3691 - 3694.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Gieseke, B. Schutt, S. Viebahn, E. Koscielniak, W. Friedrich, R. Handgretinger, and I. Muller
Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFN{gamma}R1 signaling and IDO expression
Blood,
September 15, 2007;
110(6):
2197 - 2200.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Jones, N. Horwood, A. Cope, and F. Dazzi
The Antiproliferative Effect of Mesenchymal Stem Cells Is a Fundamental Property Shared by All Stromal Cells
J. Immunol.,
September 1, 2007;
179(5):
2824 - 2831.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Batten, N. A Rosenthal, and M. H Yacoub
Immune response to stem cells and strategies to induce tolerance
Phil Trans R Soc B,
August 29, 2007;
362(1484):
1343 - 1356.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Haniffa, X.-N. Wang, U. Holtick, M. Rae, J. D. Isaacs, A. M. Dickinson, C. M. U. Hilkens, and M. P. Collin
Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells
J. Immunol.,
August 1, 2007;
179(3):
1595 - 1604.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Prevosto, M. Zancolli, P. Canevali, M. R. Zocchi, and A. Poggi
Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction
Haematologica,
July 1, 2007;
92(7):
881 - 888.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Curti, S. Pandolfi, B. Valzasina, M. Aluigi, A. Isidori, E. Ferri, V. Salvestrini, G. Bonanno, S. Rutella, I. Durelli, et al.
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells
Blood,
April 1, 2007;
109(7):
2871 - 2877.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Sato, K. Ozaki, I. Oh, A. Meguro, K. Hatanaka, T. Nagai, K. Muroi, and K. Ozawa
Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells
Blood,
January 1, 2007;
109(1):
228 - 234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Zhu, F. Ji, Y. Wang, Y. Zhang, Q. Liu, J. Z. Zhang, K. Matsushima, Q. Cao, and Y. Zhang
Synovial Autoreactive T Cells in Rheumatoid Arthritis Resist IDO-Mediated Inhibition
J. Immunol.,
December 1, 2006;
177(11):
8226 - 8233.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Romani, F. Bistoni, K. Perruccio, C. Montagnoli, R. Gaziano, S. Bozza, P. Bonifazi, G. Bistoni, G. Rasi, A. Velardi, et al.
Thymosin {alpha}1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance
Blood,
October 1, 2006;
108(7):
2265 - 2274.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. van Laar and A. Tyndall
Adult stem cells in the treatment of autoimmune diseases
Rheumatology,
October 1, 2006;
45(10):
1187 - 1193.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Nauta, G. Westerhuis, A. B. Kruisselbrink, E. G. A. Lurvink, R. Willemze, and W. E. Fibbe
Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting
Blood,
September 15, 2006;
108(6):
2114 - 2120.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Nauta, A. B. Kruisselbrink, E. Lurvink, R. Willemze, and W. E. Fibbe
Mesenchymal Stem Cells Inhibit Generation and Function of Both CD34+-Derived and Monocyte-Derived Dendritic Cells
J. Immunol.,
August 15, 2006;
177(4):
2080 - 2087.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Stagg, S. Pommey, N. Eliopoulos, and J. Galipeau
Interferon-{gamma}-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell
Blood,
March 15, 2006;
107(6):
2570 - 2577.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. M. Spaggiari, A. Capobianco, S. Becchetti, M. C. Mingari, and L. Moretta
Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation
Blood,
February 15, 2006;
107(4):
1484 - 1490.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Minguell and A. Erices
Mesenchymal Stem Cells and the Treatment of Cardiac Disease
Experimental Biology and Medicine,
January 1, 2006;
231(1):
39 - 49.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Fujigaki, K. Saito, F. Lin, S. Fujigaki, K. Takahashi, B. M. Martin, C. Y. Chen, J. Masuda, J. Kowalak, O. Takikawa, et al.
Nitration and Inactivation of IDO by Peroxynitrite
J. Immunol.,
January 1, 2006;
176(1):
372 - 379.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Corcione, F. Benvenuto, E. Ferretti, D. Giunti, V. Cappiello, F. Cazzanti, M. Risso, F. Gualandi, G. L. Mancardi, V. Pistoia, et al.
Human mesenchymal stem cells modulate B-cell functions
Blood,
January 1, 2006;
107(1):
367 - 372.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Eliopoulos, J. Stagg, L. Lejeune, S. Pommey, and J. Galipeau
Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice
Blood,
December 15, 2005;
106(13):
4057 - 4065.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Poggi, C. Prevosto, A.-M. Massaro, S. Negrini, S. Urbani, I. Pierri, R. Saccardi, M. Gobbi, and M. R. Zocchi
Interaction between Human NK Cells and Bone Marrow Stromal Cells Induces NK Cell Triggering: Role of NKp30 and NKG2D Receptors
J. Immunol.,
November 15, 2005;
175(10):
6352 - 6360.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Potula, L. Poluektova, B. Knipe, J. Chrastil, D. Heilman, H. Dou, O. Takikawa, D. H. Munn, H. E. Gendelman, and Y. Persidsky
Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis
Blood,
October 1, 2005;
106(7):
2382 - 2390.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. R Blazar and W. J Murphy
Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD)
Phil Trans R Soc B,
September 29, 2005;
360(1461):
1747 - 1767.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Zappia, S. Casazza, E. Pedemonte, F. Benvenuto, I. Bonanni, E. Gerdoni, D. Giunti, A. Ceravolo, F. Cazzanti, F. Frassoni, et al.
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy
Blood,
September 1, 2005;
106(5):
1755 - 1761.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Hainz, P. Obexer, C. Winkler, P. Sedlmayr, O. Takikawa, H. Greinix, A. Lawitschka, U. Putschger, D. Fuchs, S. Ladisch, et al.
Monocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation
Blood,
May 15, 2005;
105(10):
4127 - 4134.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Glennie, I. Soeiro, P. J. Dyson, E. W.-F. Lam, and F. Dazzi
Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells
Blood,
April 1, 2005;
105(7):
2821 - 2827.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Terness, J.-J. Chuang, T. Bauer, L. Jiga, and G. Opelz
Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO?
Blood,
March 15, 2005;
105(6):
2480 - 2486.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Aggarwal and M. F. Pittenger
Human mesenchymal stem cells modulate allogeneic immune cell responses
Blood,
February 15, 2005;
105(4):
1815 - 1822.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. McDevitt
Specific antigen vaccination to treat autoimmune disease
PNAS,
October 5, 2004;
101(suppl_2):
14627 - 14630.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|